-Collaboration brings together breakthrough gene editing technology and leading natural killer (NK) cell and T cell discovery, development, and manufacturing capabilities- -Companies to co-develop and co-commercialize...
Gene editing
EdiGene Raises Approximately USD 62 Million in Series B Plus Financing and Expands Operation Locations to Advance and Scale Up Clinical Translation of Gene Editing Technologies
BEIJING & CAMBRIDGE, Mass.–(BUSINESS WIRE)–EdiGene, Inc. (“Company”, or “EdiGene”), today announced the successful completion of an RMB 400 million (approximately USD 62 million) Series B Plus financing...
